• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.

作者信息

Viner C V, Selby P J, Zulian G B, Gore M E, Butcher M E, Wootton C M, McElwain T J

机构信息

Section of Medicine, Institute of Cancer Research, Sutton, Surrey, UK.

出版信息

Cancer Chemother Pharmacol. 1990;25(6):449-53. doi: 10.1007/BF00686058.

DOI:10.1007/BF00686058
PMID:2138064
Abstract

A total of 33 patients with myeloma receiving treatment with high-dose melphalan (140-200 mg/m2 i.v.) were given the 5HT3 antagonist Ondansetron (Glaxo) as an antiemetic. In 42% of patients, emetic episodes were either abolished (15%) or reduced to two or less (27%). Efficacy was not related to scheduling (two regimens) or total dose. No sedative or other significant side effects were seen. Ondansetron is a highly effective non-sedative antiemetic that justifies further assessment in combination with other antiemetics in patients receiving cytotoxic drugs associated with the production of severe nausea and vomiting.

摘要

相似文献

1
Ondansetron--a new safe and effective antiemetic in patients receiving high-dose melphalan.
Cancer Chemother Pharmacol. 1990;25(6):449-53. doi: 10.1007/BF00686058.
2
Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.昂丹司琼与昂丹司琼联合地塞米松在含顺铂化疗中作为预防性止吐药的比较。
Lancet. 1991 Aug 24;338(8765):487-90. doi: 10.1016/0140-6736(91)90555-4.
3
Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study.阿瑞匹坦用于控制多发性骨髓瘤患者自体外周血干细胞移植中使用大剂量美法仑所致的延迟性恶心和呕吐：一项II期研究。
Support Care Cancer. 2014 Nov;22(11):2911-6. doi: 10.1007/s00520-014-2248-6. Epub 2014 May 17.
4
A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.昂丹司琼与甲氧氯普胺预防环磷酰胺、氟尿嘧啶和多柔比星或表柔比星化疗所致呕吐的随机双盲对照研究。
J Clin Oncol. 1990 Jun;8(6):1063-9. doi: 10.1200/JCO.1990.8.6.1063.
5
Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.三种口服剂量昂丹司琼预防环磷酰胺-阿霉素化疗相关恶心和呕吐的评估。
J Clin Oncol. 1991 Jul;9(7):1268-74. doi: 10.1200/JCO.1991.9.7.1268.
6
A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.静脉注射选择性5-羟色胺拮抗剂昂丹司琼与静脉注射胃复安预防大剂量顺铂化疗相关恶心和呕吐的单盲比较。
J Clin Oncol. 1991 May;9(5):721-8. doi: 10.1200/JCO.1991.9.5.721.
7
Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting.昂丹司琼（GR 38032F）的疗效及血清素在顺铂所致恶心和呕吐中的作用。
N Engl J Med. 1990 Mar 22;322(12):810-6. doi: 10.1056/NEJM199003223221204.
8
Ondansetron. Therapeutic use as an antiemetic.昂丹司琼。作为止吐药的治疗用途。
Drugs. 1991 Apr;41(4):574-95. doi: 10.2165/00003495-199141040-00006.
9
[Clinical evaluation of ondansetron (injection of a single intravenous dose) against nausea and emesis associated with anti-cancer drugs--dose-finding study in patients receiving cisplatin].[昂丹司琼（单次静脉注射）对抗癌药物所致恶心和呕吐的临床评价——顺铂治疗患者的剂量探索研究]
Gan To Kagaku Ryoho. 1992 Aug;19(9):1333-45.
10
Oral ondansetron for the control of delayed emesis after cisplatin. Report of a phase II study and a review of completed trials to manage delayed emesis.
Cancer. 1992 Aug 15;70(4 Suppl):1012-6.

引用本文的文献

1
Pharmacological Agents Affecting Emesis : A Review (Part II).影响呕吐的药物制剂：综述（第二部分）
Drugs. 1992 Apr;43(4):443-463. doi: 10.2165/00003495-199243040-00003.
2
Efficacy of aprepitant in preventing nausea and vomiting due to high-dose melphalan-based conditioning for allogeneic hematopoietic stem cell transplantation.阿瑞匹坦预防异基因造血干细胞移植中基于大剂量美法仑预处理所致恶心和呕吐的疗效。
Int J Hematol. 2014 Apr;99(4):457-62. doi: 10.1007/s12185-014-1538-6. Epub 2014 Mar 12.
3
Antiemetic therapy for multiple-day chemotherapy and high-dose chemotherapy with stem cell transplant: review and consensus statement.

本文引用的文献

1
High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.大剂量静脉注射美法仑治疗浆细胞白血病和骨髓瘤。
Lancet. 1983 Oct 8;2(8354):822-4. doi: 10.1016/s0140-6736(83)90739-0.
2
Multiple myeloma treated with high dose intravenous melphalan.采用大剂量静脉注射美法仑治疗的多发性骨髓瘤。
Br J Haematol. 1987 May;66(1):55-62. doi: 10.1111/j.1365-2141.1987.tb06890.x.
3
High-dose melphalan and autologous bone marrow transplant as treatment for refractory Hodgkin's disease.大剂量美法仑和自体骨髓移植治疗难治性霍奇金淋巴瘤。
多日化疗及干细胞移植大剂量化疗的止吐治疗：综述与共识声明
Support Care Cancer. 2005 Feb;13(2):112-6. doi: 10.1007/s00520-004-0704-4. Epub 2004 Oct 9.
4
Open probability of homomeric murine 5-HT3A serotonin receptors depends on subunit occupancy.同源性小鼠5-羟色胺3A受体的开放概率取决于亚基占有率。
J Physiol. 2001 Sep 1;535(Pt 2):427-43. doi: 10.1111/j.1469-7793.2001.00427.x.
5
Oncology.肿瘤学
Postgrad Med J. 1993 Feb;69(808):85-94. doi: 10.1136/pgmj.69.808.85.
6
An open, randomized study to compare the efficacy and tolerability of tropisetron with that of a metoclopramide-containing antiemetic cocktail in the prevention of cisplatin-induced emesis.
Cancer Chemother Pharmacol. 1994;33(4):298-302. doi: 10.1007/BF00685903.
7
Ondansetron. Therapeutic use as an antiemetic.昂丹司琼。作为止吐药的治疗用途。
Drugs. 1991 Apr;41(4):574-95. doi: 10.2165/00003495-199141040-00006.
8
The role of nitric oxide in serotonin-induced relaxations in the canine terminal ileum and ileocolonic junction.一氧化氮在犬回肠末端和回结肠连接处5-羟色胺诱导的舒张中的作用。
Naunyn Schmiedebergs Arch Pharmacol. 1991 Dec;344(6):716-9. doi: 10.1007/BF00174756.
J Clin Oncol. 1986 Apr;4(4):612.
4
Melphalan and total body irradiation (TBI) versus cyclophosphamide and TBI as conditioning for allogeneic matched sibling bone marrow transplants for acute myeloblastic leukaemia in first remission.美法仑与全身照射（TBI）对比环磷酰胺与TBI作为首次缓解期急性髓细胞白血病异基因匹配同胞骨髓移植预处理方案的研究
Bone Marrow Transplant. 1988 Jan;3(1):21-9.
5
The efficacy of GR38032F, an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting.5-羟色胺-3（5-HT3）拮抗剂GR38032F预防顺铂（CDDP）引起的恶心和呕吐的疗效。
Eur J Cancer Clin Oncol. 1988 Aug;24(8):1383-4. doi: 10.1016/0277-5379(88)90235-0.
6
Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.血清素拮抗剂GR-C507/75（GR38032F）在接受抗癌化疗的患者中用作止吐药时的剂量范围评估。
J Clin Oncol. 1988 Apr;6(4):659-62. doi: 10.1200/JCO.1988.6.4.659.
7
Prevention of emesis in patients receiving cytotoxic drugs by GR38032F, a selective 5-HT3 receptor antagonist.
Lancet. 1987 Jun 27;1(8548):1461-3. doi: 10.1016/s0140-6736(87)92208-2.
8
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonist.新型选择性5HT-3拮抗剂BRL43694的药代动力学及止吐疗效
Br J Cancer. 1988 Nov;58(5):651-3. doi: 10.1038/bjc.1988.278.
9
The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694.5-羟色胺3受体拮抗剂BRL 43694的止吐潜力
Br J Cancer. 1988 Nov;58(5):644-50. doi: 10.1038/bjc.1988.277.
10
Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin.血清素拮抗剂GR38032F用于控制顺铂所致呕吐的II期试验。
J Natl Cancer Inst. 1989 Jan 4;81(1):42-6. doi: 10.1093/jnci/81.1.42.